Radiolabeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC).

Management expects typical Q3 to Q4 operating ratio degradation to be in the "300 to 400 basis point" range, with Batteh noting, "With October trending a little bit lower this year than what we've ...